Mycenax Biotech Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Pei-Jiun Chen
Chief executive officer
NT$7.8m
Total compensation
| CEO salary percentage | 56.4% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.3yrs |
| Board average tenure | 2.4yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -NT$536m |
| Jun 30 2024 | n/a | n/a | -NT$512m |
| Mar 31 2024 | n/a | n/a | -NT$577m |
| Dec 31 2023 | NT$8m | NT$4m | -NT$683m |
| Sep 30 2023 | n/a | n/a | -NT$713m |
| Jun 30 2023 | n/a | n/a | -NT$764m |
| Mar 31 2023 | n/a | n/a | -NT$713m |
| Dec 31 2022 | NT$8m | NT$4m | -NT$454m |
Compensation vs Market: Pei-Jiun's total compensation ($USD239.51K) is above average for companies of similar size in the TW market ($USD140.71K).
Compensation vs Earnings: Pei-Jiun's compensation has increased whilst the company is unprofitable.
CEO
Pei-Jiun Chen
2.2yrs
Tenure
NT$7,838,000
Compensation
Ms. Pei-Jiun Chen is Representative Director of Mycenax Biotech Inc. from October 06, 2022 and serves as its Chairman since October 6, 2022 and Chief executive Officer and President. She is Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President CEO & Chairman | no data | NT$7.84m | 0.42% NT$ 38.1m | |
| Associate VP of Administration & Management Division | 4.3yrs | NT$3.03m | no data | |
| Associate Vice President of Pharmaceutical Development Division | 4.3yrs | NT$3.45m | no data | |
| Corporate Governance Officer | less than a year | no data | no data |
4.3yrs
Average Tenure
Experienced Management: 4726's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President CEO & Chairman | 2.2yrs | NT$7.84m | 0.42% NT$ 38.1m | |
| Independent Director | 2.6yrs | NT$310.00k | no data | |
| Director | less than a year | no data | no data | |
| Director | 10.5yrs | NT$70.00k | no data | |
| Director | less than a year | NT$255.00k | no data | |
| Independent Director | 11.8yrs | NT$405.00k | no data | |
| Independent Director | 5.3yrs | NT$390.00k | no data | |
| Independent Director | less than a year | no data | no data |
2.4yrs
Average Tenure
Experienced Board: 4726's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 12:30 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mycenax Biotech Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Regina Lee | Capital Securities Corporation |
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hengyu Fu | Masterlink Securities Corp. |